NurExone closes C$1.07M private placement for working capital
- NurExone raised C$1,066,078 via private placement of 1,938,326 units at C$0.55 each
- Proceeds designated for general working capital purposes with no insider participation
- Warrants exercisable at C$0.69 include acceleration clause triggered by C$1.38 share price
- Securities subject to statutory hold period expiring December 21, 2026
*this image is generated using AI for illustrative purposes only.
NurExone Biologic Inc. (TSXV: NRX) has closed a non-brokered private placement raising aggregate gross proceeds of approximately C$1,066,078. The biopharmaceutical company issued 1,938,326 units at a price of C$0.55 per unit to fund general working capital purposes.
The closing is subject to final acceptance by the TSX Venture Exchange. No insiders participated in the offering, and the company did not pay any finder’s fees in connection with the transaction.
Offering Structure
Each unit consists of one common share and one common share purchase warrant. The warrants entitle holders to purchase one common share at an exercise price of C$0.69 per share for a period of 36 months from the closing date.
| Component | Details |
|---|---|
| Units Issued | 1,938,326 |
| Price Per Unit | C$0.55 |
| Warrant Exercise Price | C$0.69 |
| Warrant Term | 36 months |
| Statutory Hold Period | 4 months and 1 day |
All securities issued under the offering are subject to a statutory hold period of four months and one day from the closing date, expiring on December 21, 2026.
Warrant Acceleration Clause
The warrants include an acceleration provision tied to trading performance. If the daily volume-weighted average trading price of the common shares on the TSX Venture Exchange equals or exceeds C$1.38 for any period of 20 consecutive trading days, the company may accelerate the expiry date of the warrants.
Upon providing written notice to warrant holders, the expiry date accelerates to 30 days following the date of the notice. If the warrants are not exercised by this accelerated expiry date, they will expire and be of no further force or effect.
What the Numbers Show
The warrant exercise price of C$0.69 represents a 25.5% premium over the unit subscription price of C$0.55. This structure provides immediate equity capital while creating upside potential for investors if the share price appreciates above the exercise threshold within the three-year window.
Company Background
NurExone is developing exosome-based regenerative therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. The company holds Orphan Drug Designation and aims to advance clinical trials in the U.S. and Europe through its U.S. subsidiary, Exo-Top Inc.
How will the C$1 million in working capital specifically accelerate the timeline for ExoPTEN's upcoming clinical trials in the U.S. and Europe?
What is the potential impact on existing shareholders given the 25.5% warrant exercise premium and the 4-month statutory hold period?
Could the warrant acceleration clause, triggered by a C$1.38 price threshold, create selling pressure or dilution concerns if the stock rallies significantly?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
